Reversing imatinib⇔s immunosuppressive effects by modulating type I IFN signaling

David A. Largaespada

doi:10.1158/2326-6066.CIR-21-0177

Reversing imatinib⇔s immunosuppressive effects by modulating type I IFN signaling

David A. Largaespada

Pediatrics - Hematology

Research output: Contribution to journal › Short survey › peer-review

Abstract

Signal pathway inhibition is a well-validated approach for treating cancers driven by activated kinases such as KIT. However, kinase inhibitors may make tumor cells less responsive to tumor immune surveillance and less sensitive to immunotherapies. In this issue, Liu and colleagues report that, in a mouse model, inhibition of oncogenic KIT in gastrointestinal stromal tumors reduces type I interferon (IFN) production and signaling, and the effectiveness of the immune system in controlling tumor growth. They were able to partially overcome the immunosuppressive effects of KIT inhibition using agonists of the type I IFN response, pointing the way toward intelligently combining kinase inhibitors and immune modulators for therapy.

Original language	English (US)
Pages (from-to)	489
Number of pages	1
Journal	Cancer Immunology Research
Volume	9
Issue number	5
DOIs	https://doi.org/10.1158/2326-6066.CIR-21-0177
State	Published - May 1 2021

Bibliographical note

Funding Information:
D.A. Largaespada reports other support from NeoClone Biotechnology, Inc., Luminary Therapeutics, Inc., Recombinetics, Inc., Luminary Therapeutics, Inc., Styx Biotechnologies, Inc., and Immusoft, Inc. and grants from Genentech, Inc. outside the submitted work.

Publisher Copyright:
2021 American Association for Cancer Research.

PubMed: MeSH publication types

Journal Article
Comment

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access

10.1158/2326-6066.CIR-21-0177

OpenUrl availability

Full text

Cite this

@article{81f001228ebd404b8d5b4fd5cd9157bc,

title = "Reversing imatinib⇔s immunosuppressive effects by modulating type I IFN signaling",

abstract = "Signal pathway inhibition is a well-validated approach for treating cancers driven by activated kinases such as KIT. However, kinase inhibitors may make tumor cells less responsive to tumor immune surveillance and less sensitive to immunotherapies. In this issue, Liu and colleagues report that, in a mouse model, inhibition of oncogenic KIT in gastrointestinal stromal tumors reduces type I interferon (IFN) production and signaling, and the effectiveness of the immune system in controlling tumor growth. They were able to partially overcome the immunosuppressive effects of KIT inhibition using agonists of the type I IFN response, pointing the way toward intelligently combining kinase inhibitors and immune modulators for therapy.",

author = "Largaespada, {David A.}",

note = "Funding Information: D.A. Largaespada reports other support from NeoClone Biotechnology, Inc., Luminary Therapeutics, Inc., Recombinetics, Inc., Luminary Therapeutics, Inc., Styx Biotechnologies, Inc., and Immusoft, Inc. and grants from Genentech, Inc. outside the submitted work. Publisher Copyright: 2021 American Association for Cancer Research.",

year = "2021",

month = may,

day = "1",

doi = "10.1158/2326-6066.CIR-21-0177",

language = "English (US)",

volume = "9",

pages = "489",

journal = "Cancer Immunology Research",

issn = "2326-6066",

publisher = "American Association for Cancer Research Inc.",

number = "5",

}

TY - JOUR

T1 - Reversing imatinib⇔s immunosuppressive effects by modulating type I IFN signaling

AU - Largaespada, David A.

N1 - Funding Information: D.A. Largaespada reports other support from NeoClone Biotechnology, Inc., Luminary Therapeutics, Inc., Recombinetics, Inc., Luminary Therapeutics, Inc., Styx Biotechnologies, Inc., and Immusoft, Inc. and grants from Genentech, Inc. outside the submitted work. Publisher Copyright: 2021 American Association for Cancer Research.

PY - 2021/5/1

Y1 - 2021/5/1

N2 - Signal pathway inhibition is a well-validated approach for treating cancers driven by activated kinases such as KIT. However, kinase inhibitors may make tumor cells less responsive to tumor immune surveillance and less sensitive to immunotherapies. In this issue, Liu and colleagues report that, in a mouse model, inhibition of oncogenic KIT in gastrointestinal stromal tumors reduces type I interferon (IFN) production and signaling, and the effectiveness of the immune system in controlling tumor growth. They were able to partially overcome the immunosuppressive effects of KIT inhibition using agonists of the type I IFN response, pointing the way toward intelligently combining kinase inhibitors and immune modulators for therapy.

AB - Signal pathway inhibition is a well-validated approach for treating cancers driven by activated kinases such as KIT. However, kinase inhibitors may make tumor cells less responsive to tumor immune surveillance and less sensitive to immunotherapies. In this issue, Liu and colleagues report that, in a mouse model, inhibition of oncogenic KIT in gastrointestinal stromal tumors reduces type I interferon (IFN) production and signaling, and the effectiveness of the immune system in controlling tumor growth. They were able to partially overcome the immunosuppressive effects of KIT inhibition using agonists of the type I IFN response, pointing the way toward intelligently combining kinase inhibitors and immune modulators for therapy.

UR - http://www.scopus.com/inward/record.url?scp=85105254019&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85105254019&partnerID=8YFLogxK

U2 - 10.1158/2326-6066.CIR-21-0177

DO - 10.1158/2326-6066.CIR-21-0177

M3 - Short survey

C2 - 33941535

AN - SCOPUS:85105254019

SN - 2326-6066

VL - 9

SP - 489

JO - Cancer Immunology Research

JF - Cancer Immunology Research

IS - 5

ER -

Reversing imatinib⇔s immunosuppressive effects by modulating type I IFN signaling

Abstract

Bibliographical note

PubMed: MeSH publication types

UN SDGs

Access

OpenUrl availability

Other files and links

Fingerprint

Cite this